exaluren
exaluren: developed by 1 company · 1 clinical trial tracked.
exaluren evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect exaluren to ELOX; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could exaluren → ELOX affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Alport Syndrome, X-Linked
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) Alport Syndrome, X-Linked | Phase 2 |
Clinical Trials (1)
A Randomized, Double-Blind, Placebo-Controlled, Delayed-Start Study to Evaluate the Efficacy and Safety of Exaluren in Alport Syndrome Patients With Nonsense Mutations in COL4A3/4/5 Genes
Primary endpoint: The change in the degree of podocyte foot process effacement
InterventionalRandomizedquadruple24 targetStarted 2026-06Completion 2027-1212 sites · United Kingdom, United StatesEloxx Pharmaceuticals, Inc.
Frequently asked questions
Who is developing exaluren?
exaluren is being developed by Eloxx Pharmaceuticals, Inc..
How many clinical trials involve exaluren?
BioSniper tracks 1 clinical trial involving exaluren.